Cite
Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma
MLA
Magnus Nilsson, et al. “Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma.” Drug Design, Development and Therapy, vol. 16, Aug. 2022, pp. 2901–17. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5e0c74bc776adaba8bf5ad2a70652436&authtype=sso&custid=ns315887.
APA
Magnus Nilsson, Magdalena Rhedin, Ramon Hendrickx, Susanne Berglund, Antonio Piras, Parmis Blomgran, Anders Cavallin, Mia Collins, Göran Dahl, Bilel Dekkak, Therese Ericsson, Niklas Hagberg, Ann Aurell Holmberg, Agnes Leffler, Anders J Lundqvist, Thomais Markou, James Pinkerton, Lars Rönnblom, Stacey Siu, … Annika Borde. (2022). Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Design, Development and Therapy, 16, 2901–2917.
Chicago
Magnus Nilsson, Magdalena Rhedin, Ramon Hendrickx, Susanne Berglund, Antonio Piras, Parmis Blomgran, Anders Cavallin, et al. 2022. “Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma.” Drug Design, Development and Therapy 16 (August): 2901–17. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5e0c74bc776adaba8bf5ad2a70652436&authtype=sso&custid=ns315887.